Transmembrane mucin MUC1 overexpression and its association with CD10+ myeloid cells, transforming growth factor-β1 expression, and tumor budding grade in colorectal cancer

Cancer Science

Volumn 104, Issue 7, 2013, Pages 958-964

  Khanh, Do Trong ^a   Mekata, Eiji ^a   Mukaisho, Ken Ichi ^a   Sugihara, Hiroyuki ^a   Shimizu, Tomoharu ^a   Shiomi, Hisanori ^a   Murata, Satoshi ^a   Naka, Shigeyuki ^a   Yamamoto, Hiroshi ^a   Endo, Yoshihiro ^a   Tani, Tohru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MEMBRANE PROTEIN; MUCIN 1; MUCIN 2; MUCIN 4; MUCIN 5AC; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KERATINS; MALE; MIDDLE AGED; MUCIN-1; MYELOID CELLS; NEPRILYSIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84880713273     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12170     Document Type: Article

References (32)

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th edn. USA: Springer, 2010.
2. Ueno H, Mochizuki H, Akagi Y et al. Optimal colorectal cancer staging criteria in TNM classification. J Clin Oncol 2012; 30: 1519-26.
3. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004; 23: 77-99.
4. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12: 319-30.
5. Niv Y. MUC1 and colorectal cancer pathophysiology considerations. World J Gastroenterol 2008; 14: 2139-41.
6. Duncan TJ, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol 2007; 5: 31.
7. Baldus SE, Mönig SP, Hanisch FG et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology 2002; 40: 440-9.
8. Baldus SE, Mönig SP, Huxel S et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 2004; 10: 2790-6.
9. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998; 4: 43-9.
10. Poh TW, Bradley JM, Mukherjee P, Gendler SJ. Lack of Muc1-regulated beta-catenin stability results in aberrant expansion of CD11b+Gr1 + myeloid-derived suppressor cells from the bone marrow. Cancer Res 2009; 69: 3554-62.
11. Roy LD, Sahraei M, Subramani DB et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011; 30: 1449-59.
12. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 2005; 47: 17-24.
13. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 1996; 49: 560-4.
14. Manne U, Weiss HL, Grizzle WE. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. Clin Cancer Res 2000; 6: 4017-25.
15. Iwase T, Kushima R, Mukaisho K, Mitsufuji S, Okanoue T, Hattori T. Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms. Pathol Res Pract 2005; 201: 83-91.
16. Kang H, Min BS, Lee KY et al. Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma. Ann Surg Oncol 2011; 18: 711-9.
17. Shanmugam C, Jhala NC, Katkoori VR et al. Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer 2010; 116: 3577-86.
18. Kocer B, Soran A, Erdogan S et al. Expression of MUC5AC in colorectal carcinoma and relationship with prognosis. Pathol Int 2002; 52: 470-7.
19. Bu XD, Li N, Tian XQ et al. Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma. World J Gastroenterol 2010; 16: 4089-94.
20. + myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci 2011; 102: 1724-33.
21. Khanh DT, Mekata E, Mukaisho K et al. Myeloid cells positive for CD10 at invasion front can predict poor outcome in stage II colorectal cancer. Int J Clin Oncol 2012; 17: 240-9.
22. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 1996; 74: 753-8.
23. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10: 554-67.
24. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993; 36: 627-35.
25. Wöhlke M, Schiffmann L, Prall F. Aggressive colorectal carcinoma phenotypes of invasion can be assessed reproducibly and effectively predict poor survival: interobserver study and multivariate survival analysis of a prospectively collected series of 299 patients after potentially curative resections with long-term follow-up. Histopathology 2011; 59: 857-66.
26. Leteurtre E, Gouyer V, Rousseau K et al. Differential mucin expression in colon carcinoma HT-29 clones with variable resistance to 5-fluorouracil and methotrexate. Biol Cell 2004; 96: 145-51.
27. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874-85.
28. Rahn JJ, Chow JW, Horne GJ et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis 2005; 22: 475-83.
29. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50: 151-62.
30. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995; 129: 255-65.
31. Ye Q, Yan Z, Liao X et al. MUC1induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13. Lab Invest 2011; 91: 778-87.
32. Li Y, Bharti A, Chen D, Gong J, Kufe D. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 1998; 18: 7216-24.